John M. Domagala - Concepedia

Author

John M. Domagala

Pfizer (United States)

Also Known As

JOHN M. DOMAGALA, John Domagala, John M Domagala, John M. Domagala

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Public Health Institute Warde Medical Laboratory NAEJA-RGM Pharmaceuticals (Canada)National Institutes of Health

About

John M. Domagala is an author at Pfizer (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	1.4K
2	Natural Sciences	18	24	884
3	Biochemistry	17	20	768
4	Engineering	10	10	191
5	Health Sciences	4	4	315

John M. Domagala

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of <i>Mycobacterium bovis</i> BCG and <i>Staphylococcus aureus</i> Yuzhi Dong, Xilin Zhao, John M. Domagala, Antimicrobial Agents and Chemotherapy	1999	281
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay John M. Domagala, Lori Doyle Hanna, Carl L. Heifetz, Journal of Medicinal Chemistry	1986	265
Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS William G. Rice, Jeffrey G. Supko, Louis Malspeis, Science Medicinal ChemistryZinc Finger-reactive CompoundsNeurovirologyMedicineHuman Retrovirus	1995	231
DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance Xilin Zhao, Chen Xu, John M. Domagala, Proceedings of the National Academy of Sciences	1997	211
Selection of Antibiotic‐Resistant Bacterial Mutants: Allelic Diversity among Fluoroquinolone‐Resistant Mutations Jianfeng Zhou, Yuzhi Dong, Xilin Zhao, The Journal of Infectious Diseases Antibiotic ResistanceDrug ResistanceAntimicrobial TherapyAllelic DiversityGyra Protein	2000	147
Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids Joseph P. Sanchez, John M. Domagala, Susan E. Hagen, Journal of Medicinal Chemistry Antibacterial AgentsBioorganic ChemistryAntibacterial ActivityBenzoxazine 10-PositionAntimicrobial Chemotherapy	1988	135
Fluoroquinolone Action against Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and Resistance Yuzhi Dong, Chen Xu, Xilin Zhao, Antimicrobial Agents and Chemotherapy Lethal Dna BreaksAntimicrobial SusceptibilityHealth SciencesM. TuberculosisMycobacterium Tuberculosis	1998	122
Fluoroquinolone Action against Clinical Isolates of <i>Mycobacterium tuberculosis</i> : Effects of a C-8 Methoxyl Group on Survival in Liquid Media and in Human Macrophages Ben Zhao, Richard Pine, John M. Domagala, Antimicrobial Agents and Chemotherapy	1999	97
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure activity relationships at N1 for the quinolone antibacterials John M. Domagala, Carl L. Heifetz, Marland P. Hutt, Journal of Medicinal Chemistry	1988	96
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity and antimicrobial activity Mark J. Suto, John M. Domagala, Gregory E. Roland, Journal of Medicinal Chemistry	1992	93

Page 1